Immunotherapy updates in pancreatic cancer: are we there yet?
about
Harnessing immunosurveillance: current developments and future directions in cancer immunotherapyComplex role for the immune system in initiation and progression of pancreatic cancer.CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancerPancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapyTargeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumorsClinical studies applying cytokine-induced killer cells for the treatment of gastrointestinal tumors.Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer.FOLFIRINOX - a new paradigm in the treatment of pancreatic cancer.Immune-based therapies in pancreatic and colorectal cancers and biomarkers of responsiveness.Strategies to relieve immunosuppression in pancreatic cancer.Control of Apoptosis in Treatment and Biology of Pancreatic Cancer.T cell optimization for the treatment of pancreatic cancer.Immunotherapy for pancreatic cancer.Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer.Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer.Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.Pancreatic cancer: Update on immunotherapies and algenpantucel-L.A self antigen reopens the games in pancreatic cancer.Vaccine therapy for pancreatic cancer.Immunosuppressive CD14+HLA-DRlo/neg monocytes are elevated in pancreatic cancer and "primed" by tumor-derived exosomes.
P2860
Q27021570-83593AC1-8BAF-4AD8-B04D-D053C18A042AQ34093784-FF501537-EBDB-4EB3-800C-AB537AB4F3FBQ34279134-13D658C4-B2D5-4696-994F-1B0548ECADF5Q34431614-B06B190E-5109-4C0F-8088-3087C8AF2BD2Q34539541-9C934DF1-7218-45E0-A60D-CCCCF0C3995FQ35886496-406EEA0B-B139-4F6E-9A06-5A463B9248E8Q36869880-282803BC-38FD-4FF3-9D7B-36CDE9F4CA82Q37704879-4CD46A9D-3B9F-4C56-8CBD-27885FABD1B6Q38221692-77FF0EA0-B559-48E9-8563-F2C5F6EFEBD8Q38247470-9A053363-2596-4BD1-B33D-05D770769305Q38249339-697B7E86-D042-4F11-885F-BD303D8DD2F7Q38445328-E2526CDF-DDE7-4682-ACEF-AF97A0EEFF27Q38553219-65D192F0-0FAA-4574-B0C2-D7CA540A5DADQ38638035-0CC7ED51-BCC4-44FC-BF94-3E22B525E9EBQ38722325-9CBE7E50-C368-4F5D-872B-5818DF4170E7Q38729867-5EE80162-FB14-4ADA-A02C-1F593B1A9429Q38829403-B571265D-E78A-4BA0-A62B-BE6F7F8E4005Q39390859-1923F05C-E02F-4436-978D-64C5ACF3922DQ40261599-51D147DE-9882-4745-AE50-7ADB68E8EB50Q41765420-8976032E-C0B3-4702-B82F-92724B6DAB2DQ42660104-C650DEE1-5C17-4A41-BE86-C88E8EA646DBQ43090726-A7258D23-9230-4EA7-9239-77D2E2CD04D8
P2860
Immunotherapy updates in pancreatic cancer: are we there yet?
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Immunotherapy updates in pancreatic cancer: are we there yet?
@ast
Immunotherapy updates in pancreatic cancer: are we there yet?
@en
type
label
Immunotherapy updates in pancreatic cancer: are we there yet?
@ast
Immunotherapy updates in pancreatic cancer: are we there yet?
@en
prefLabel
Immunotherapy updates in pancreatic cancer: are we there yet?
@ast
Immunotherapy updates in pancreatic cancer: are we there yet?
@en
P2093
P2860
P356
P1476
Immunotherapy updates in pancreatic cancer: are we there yet?
@en
P2093
Gabriela R Rossi
Krishna Soujanya Gunturu
Muhammad Wasif Saif
P2860
P356
10.1177/1758834012462463
P577
2013-01-01T00:00:00Z